Public list: Pharma Startups (6570) Cancer Therapeutics (1180)
Ribon Therapeutics is targeting the discovery and development of monoPARP (mono ADP-ribose polymerase) inhibitors to block cancer cells' fundamental ability to survive under stress.
Company (Alive / Active)
Phone: 617-914-8700
99 Hayden Avenue
Lexington, 02421
Massachusetts, United States
Per Week | Per Month | Per 6 Months | Per Year | |
---|---|---|---|---|
Rank | Login to see details | |||
Page Views Per Million | Login to see details | |||
Page Views Per User | Login to see details | |||
Reach Per Million | Login to see details |
Title | Application Date | Patent Date | Status (Patent / Application) |
---|---|---|---|
Pyridazinones as parp7 inhibitors | Oct 24, 2019 | Dec 22, 2020 | Patent |
Quinazolinones as parp14 inhibitors | Dec 20, 2018 | Feb 18, 2020 | Patent |
Pyridazinones as parp7 inhibitors | Apr 29, 2019 | Feb 04, 2020 | Patent |
Quinazolinones as parp14 inhibitors | Jan 06, 2020 | Application | |
Screening methods for parp modulators | Apr 29, 2019 | Application |